M
330.33
-0.90 (-0.27%)
| 前收盘价格 | 331.23 |
| 收盘价格 | 331.76 |
| 成交量 | 92,385 |
| 平均成交量 (3个月) | 404,483 |
| 市值 | 7,293,752,320 |
| 价格/销量 (P/S) | 37.78 |
| 股市价格/股市净资产 (P/B) | 9.36 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 营业毛利率 | -258.64% |
| 营业利益率 (TTM) | -64.84% |
| 稀释每股收益 (EPS TTM) | -21.92 |
| 总债务/股东权益 (D/E MRQ) | 15.85% |
| 流动比率 (MRQ) | 6.10 |
| 营业现金流 (OCF TTM) | -455.57 M |
| 杠杆自由现金流 (LFCF TTM) | -296.99 M |
| 资产报酬率 (ROA TTM) | -36.98% |
| 股东权益报酬率 (ROE TTM) | -80.35% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Madrigal Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.8
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.75 |
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 8.79% |
| 机构持股比例 | 105.14% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Paulson & Co. Inc. | 31 Dec 2024 | 2,042,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 469.00 (Citigroup, 41.98%) | 购买 |
| 中 | 450.50 (36.38%) | |
| 低 | 405.00 (HC Wainwright & Co., 22.61%) | 购买 |
| 平均值 | 442.50 (33.96%) | |
| 总计 | 6 购买 | |
| 平均价格@调整类型 | 328.63 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| B. Riley Securities | 02 May 2025 | 460.00 (39.25%) | 购买 | 326.79 |
| Canaccord Genuity | 02 May 2025 | 420.00 (27.15%) | 购买 | 326.79 |
| UBS | 02 May 2025 | 458.00 (38.65%) | 购买 | 326.79 |
| JMP Securities | 24 Apr 2025 | 443.00 (34.11%) | 购买 | 319.93 |
| Citigroup | 27 Feb 2025 | 469.00 (41.98%) | 购买 | 335.74 |
| HC Wainwright & Co. | 27 Feb 2025 | 405.00 (22.60%) | 购买 | 335.74 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合